Salford Lung Health Biomarker Study
Research type
Research Study
Full title
The role of biomarkers for the early detection of lung cancer in the Salford Lung Check cohort.
IRAS ID
266895
Contact name
Seamus Grundy
Contact email
Sponsor organisation
Salford Royal NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Summary of Research
The incidence of lung cancer in Salford is 65% higher than the national average. A community based lung health check will be introduced, as part of which lung cancer risk will be assessed, using the validated Prostate Lung Colon Ovarian (PLCO) risk calculator and individuals who are high risk will be offered low dose CT screening.
The Salford Lung Health Biomarker Study will recruit attendees of the screening service who are identified as being at high risk of lung cancer. They will be asked to provide blood samples. Those who have a positive CT scan will also be asked to provide urine and saliva samples.
Samples will be used for the investigation of biomarkers including, but not limited to, circulating tumour cells (CTC), circulating free DNA (cfDNA) microRNA (miRNA), proteomics and genetic variants in DNA.
Summary of Results
The aim of this study was to develop a blood test which would aid in the diagnosis of early stage lung cancer and support efficient lung cancer screening
Background: Lung Cancer is the largest cause of cancer related death worldwide. Symptomatic patients frequently present with late stage disease which is not curable. Lung Cancer Screening has been shown to reduce lung cancer mortality. There is a need to improve the efficiency of lung cancer screening with Low Dose CT in order to maximise the number of cancers diagnosed and minimise screening related harms. One potential approach to this would be to incorporate a blood test to help predict the likelihood of a patient having or developing lung cancer.
Methods: Blood was collected from individuals attending for a Lung Health Check CT scan. Samples were processed and analysed for a wide panel of exploratory biomarkers with the aim of developing a ‘panel’ of tests which can predict lung cancer likelihood
Key findings: The initial results from this study were unable to accurately detect early stage lung cancer. Consequently funding for further work was withdrawn and the study closed early.
REC name
South East Scotland REC 01
REC reference
20/SS/0008
Date of REC Opinion
30 Jan 2020
REC opinion
Further Information Favourable Opinion